Arun Upadhyay - 02 Jan 2025 Form 4 Insider Report for Ocugen, Inc. (OCGN)

Reporting relationship: Chief Scientific Officer, Head of Research, Development and Medical
Issuer ticker: OCGN
Reported as of: 02 Jan 2025
Net transaction value: -$37,241
SEC form: 4
Accepted by SEC: 06 Jan 2025, 17:02:25 UTC
Prior SEC filing: 26 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Arun Upadhyay by Shankar Musunuri, his attorney-in-fact

Key filing fact

Arun Upadhyay filed Form 4 for Ocugen, Inc. (OCGN) on 06 Jan 2025.

Key facts

This page summarizes Arun Upadhyay's Form 4 filing for Ocugen, Inc. (OCGN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2025, 17:02.

Change

Previous filing in this sequence was filed on 26 Sep 2024.
Current net transaction value: -$37,241.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCGN transaction

Common Stock

Tax liability

Transaction value: $37,241
Shares: -41,633
Change %: -12%
Price: $0.8945
Shares after: 306,197
Date: 03 Jan 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCGN transaction Derivative

Option (Right to Buy)

Award

Transaction value: $0
Shares: +730,994
Change %
Price: $0.000000
Shares after: 730,994
Date: 02 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 730,994
Exercise price: $0.9000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates.

SEC remarks

Chief Scientific Officer, Head of Research, Development and Medical